Anagenesis Biotechnologies Overview
- Year Founded
-
2011
- Status
-
Out of Business
- Employees
-
9
- Latest Deal Type
-
Liquidation
Anagenesis Biotechnologies General Information
Description
Developer of novel treatments designed for genetic and age-related muscle degenerative diseases. The company owns a proprietary platform technology, to guide the differentiation of pluripotent stem cells (iPSC) into paraxial mesoderm multipotent cells, which are the shared precursors of various tissues, such as skeletal muscle, ribs, vertebrae, dermis, endothelium & brown fat, thereby enabling physicians to mimic the natural process of muscle formation.
Contact Information
Website
www.anagenesis-biotech.comCorporate Office
- Parc d'innovation, BioParc 3
- 850 Boulevard Sébastien Brant
- 67400 Illkirch Graffenstaden
- France
Corporate Office
- Parc d'innovation, BioParc 3
- 850 Boulevard Sébastien Brant
- 67400 Illkirch Graffenstaden
- France
Anagenesis Biotechnologies Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 8. Bankruptcy: Liquidation | 05-Dec-2022 | Completed | Bankruptcy: Liquidation | |||
| 7. Later Stage VC (Series A) | 04-Dec-2018 | Completed | Startup | |||
| 6. Later Stage VC | 04-Dec-2018 | Completed | Startup | |||
| 5. Later Stage VC | 22-Nov-2016 | Completed | Startup | |||
| 4. Early Stage VC | 23-Apr-2015 | Completed | Startup | |||
| 3. Corporate | 04-Dec-2013 | Completed | Startup | |||
| 2. Accelerator/Incubator | 01-Jan-2011 | Completed | Startup | |||
| 1. University Spin-Out | 01-Jan-2011 | Completed | Startup |
Anagenesis Biotechnologies Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Preference | ||||||||
| Preference | ||||||||
| Ordinary | 472 | $35.88 | $35.88 | 1x | $35.88 | 0.5% | ||
| Preference | 3,645 | $35.88 | $35.88 | 1x | $35.88 | 3.88% |
Anagenesis Biotechnologies Patents
Anagenesis Biotechnologies Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2023237759-A1 | Dihydro[1,8]naphthyridin-7-one and pyrido[3,2-b][1,4]oxazin-3-one for use in treating cancer, and metastases in particular | Inactive | 10-Jun-2022 | ||
| EP-4289427-A1 | Dihydro[1,8]naphthyridin-7-one and pyrido[3,2-b][1,4]oxazin-3-one for use in treating cancer, and metastases in particular. | Inactive | 10-Jun-2022 | ||
| EP-4029501-A1 | Combination of polyaromatic urea derivatives and glucocorticoid or hdac inhibitor for the treatment of diseases or conditions associated with muscle cells and/or satellite cells | Inactive | 19-Jan-2021 | ||
| CA-3140017-A1 | Polyaromatic urea derivatives and their use in the treatment of muscle diseases | Pending | 19-Jul-2019 | ||
| EP-3999057-A1 | Polyaromatic urea derivatives and their use in the treatment of muscle diseases | Inactive | 19-Jul-2019 | C07D401/12 |
Anagenesis Biotechnologies Signals
Anagenesis Biotechnologies FAQs
-
When was Anagenesis Biotechnologies founded?
Anagenesis Biotechnologies was founded in 2011.
-
Where is Anagenesis Biotechnologies headquartered?
Anagenesis Biotechnologies is headquartered in Illkirch Graffenstaden, France.
-
What is the size of Anagenesis Biotechnologies?
Anagenesis Biotechnologies has 9 total employees.
-
What industry is Anagenesis Biotechnologies in?
Anagenesis Biotechnologies’s primary industry is Biotechnology.
-
Is Anagenesis Biotechnologies a private or public company?
Anagenesis Biotechnologies is a Private company.
-
What is Anagenesis Biotechnologies’s current revenue?
The current revenue for Anagenesis Biotechnologies is .
-
How much funding has Anagenesis Biotechnologies raised over time?
Anagenesis Biotechnologies has raised $21.6M.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process